A massive international study has shown that the experimental oral obesity drug orforglipron can help patients shed over 10% of their body weight, with nearly one in five losing 20% or more. Unlike most GLP-1 agonists that require injections, orforglipron comes as a once-daily pill, potentially making weight-loss treatment more accessible.
A massive international study has shown that the experimental oral obesity drug orforglipron can help patients shed over 10% of their body weight, with nearly one in five losing 20% or more. Unlike most GLP-1 agonists that require injections, orforglipron comes as a once-daily pill, potentially making weight-loss treatment more accessible. A massive international study has shown that the experimental oral obesity drug orforglipron can help patients shed over 10% of their body weight, with nearly one in five losing 20% or more. Unlike most GLP-1 agonists that require injections, orforglipron comes as a once-daily pill, potentially making weight-loss treatment more accessible.